Coronary Interventions Ulm - Coronary Chronic Total Occlusions

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04650139

Acronym

CSI

Enrollment

500

Registered

2020-12-02

Start date

2014-01-01

Completion date

2025-01-01

Last updated

2020-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Total Occlusion, Chronic Total Occlusion of Coronary Artery

Brief summary

The aim of the proposed project is to provide the long-term results after a recanalization attempt of chronically occluded coronary arteries. To investigate recanalization attempt of chronically occluded coronary arteries at the Ulm University Hospital. As shown, it is known that successful recanalization of a chronic occlusion is associated with a lower event rate (reduced mortality and the need for operative myocardial revascularization) compared to unsuccessful recanalization (drug therapy). The standard in the therapy of successfully recanalized chronic occlusions is the use of drug-releasing vascular supports.

Interventions

PROCEDUREPCI - percutaneous coronary intervention

percutaneous coronary intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients over 18 years Coronary intervention in chronic coronary artery occlusion Occlusion \> 3 months Indication for PTCA or recanalization according to guidlines such as: Symptoms of the patient Evidence of myocardial ischemia (stress ECG, scintigraphic Methods, magnetic resonance imaging, stress echocardiography) pathological intracoronary flow reserve, prognostic

Exclusion criteria

* No chronic occlusion, * Contraindication to anti-platelet therapy Acetylsalicylic acid plus clopidogrel for at least 3 months such as e.g. with florid gastrointestinal ulcer disease, History of hemorrhagic stroke or urgent non-postponable surgical intervention. Basic disease with a life expectancy of less than 12 months (here as a rule no indication for PTCA or reopening available)

Design outcomes

Primary

Measure	Time frame	Description
MACE	1 year	major adverse cardiac event

Secondary

Measure	Time frame	Description
TLR	1 year	target lesion revascularization

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026